project id: TCGA-PRAD; case submitter id: TCGA-XK-AAJR; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.96; rna integrity number: 9.6; age at index: 61; days to birth: -22643; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 22643; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1124.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 776; days to sample procurement: 0; initial weight: 10.0; sample id: 1d817e1a-de87-4936-b445-c6c88844be5d; sample submitter id: TCGA-XK-AAJR-01A; portion id: 27c59a93-fc6c-466f-bbdc-51c29e80ab1e; portion submitter id: TCGA-XK-AAJR-01A-11; slide id: 4b74631f-efcb-48ab-93ea-21ba74103f30; slide submitter id: TCGA-XK-AAJR-01Z-00-DX1; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 18.0; percent stromal cells: 55.0; percent tumor cells: 25.0; percent tumor nuclei: 75.0; section location: TOP;